Is left ventricular hypertrophy regression important? Does the tool used to detect it matter?
Left ventricular hypertrophy (LVH) has been demonstrated to define an adverse cardiovascular prognosis. However, due to poor noninvasive tools in which to accurately define LVH, the clinical manifestations dictate an inexact manner in which to either initiate therapy or to gauge the success of LVH regression. Herein, the authors define the current state of imaging modalities available to interrogate LVH and its regression, but concentrating chiefly on the "gold standard" of cardiovascular magnetic resonance imaging (CMR). The authors review the data demonstrating the importance of LVH regression. Additionally, they highlight the strengths and weaknesses of CMR via several pinnacle studies that demonstrate the ease, efficiency, and accuracy of this new noninvasive reproducible and available tool to relatively inexpensively delineate LVH. Finally, upon pharmacologic administration of an antihypertensive regimen, the authors, for the first time, define a goal of left ventricular mass reduction (in grams) for echocardiography and CMR based in part on Framingham data aiming at improving cardiovascular risk.
Nadour
Wadih
W
Division of Internal Medicine and Cardiology, Allegheny General Hospital, Pittsburgh, PA 15212, USA.
Biederman
Robert W W
RW
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000453:epidemiology; D004452:Echocardiography; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D008279:Magnetic Resonance Imaging; D012307:Risk Factors; D016896:Treatment Outcome
D000959:Antihypertensive Agents
Am J Hypertens. 2005 Dec;18(12 Pt 1):1563-9
16364826
Circulation. 2006 Mar 28;113(12):1588-96
16534012
Hypertension. 2001 Dec 1;38(6):E28-32
11751742
J Am Coll Cardiol. 2001 Dec;38(7):1829-35
11738281
Circulation. 2001 Oct 2;104(14):1615-21
11581138
Circulation. 1998 Jan 6-13;97(1):48-54
9443431
Am J Hypertens. 1993 Apr;6(4):308-13
7685176
Circulation. 2003 Oct 14;108(15):1831-8
14517164
Circulation. 1995 Feb 1;91(3):698-706
7828296
Eur Heart J. 1992 Aug;13(8):1011-9
1387084
Ann Intern Med. 1992 Nov 15;117(10):831-6
1416558
Radiology. 1988 Nov;169(2):495-8
2971985
Cardiovasc Drugs Ther. 1994 Aug;8 Suppl 3:549-56
7841088
JAMA. 1996 May 15;275(19):1507-13
8622227
Circulation. 1997 Aug 19;96(4):1330-6
9286966
Hypertension. 2008 Aug;52(2):279-86
18606908
Hypertension. 2002 Nov;40(5):673-8
12411461
Cardiology. 1992;81(4-5):291-8
1301257
Br Med J (Clin Res Ed). 1985 Jul 13;291(6488):97-104
2861880
N Engl J Med. 1990 May 31;322(22):1561-6
2139921
Am J Med. 2003 Jul;115(1):41-6
12867233
J Am Coll Cardiol. 1998 Nov;32(5):1454-9
9809962
J Hypertens. 1996 Aug;14(8):1005-10
8884556
Circulation. 1994 Oct;90(4):1786-93
7923663
JAMA. 2004 Nov 17;292(19):2350-6
15547162
J Am Coll Cardiol. 1985 Sep;6(3):572-80
3161926
J Hypertens. 1995 Oct;13(10):1091-5
8586800
J Am Soc Nephrol. 2004 Jun;15(6):1640-7
15153576
Circulation. 2001 Oct 23;104(17):2039-44
11673343
Ann Intern Med. 2007 Sep 4;147(5):311-9
17785486
Am J Cardiol. 1989 Jan 15;63(3):202-10
2521269
Hypertension. 2000 Nov;36(5):755-9
11082139
Am J Hypertens. 1995 Mar;8(3):221-8
7794570
J Am Coll Cardiol. 2004 Jun 16;43(12):2207-15
15193681
Hypertension. 1989 May;13(5 Suppl):I36-44
2490827
J Am Coll Cardiol. 1986 Jul;8(1):107-12
3711505
JAMA. 2004 Nov 17;292(19):2343-9
15547161
Am J Cardiol. 1985 Feb 15;55(5):545-9
3155902
J Hypertens. 1998 Jun;16(6):715-23
9663910
Lancet. 1990 Apr 7;335(8693):827-38
1969567
Hypertension. 1985 Jan-Feb;7(1):105-12
3156812
Circulation. 1997 Apr 15;95(8):2007-14
9133508